Genmab — Januar 2020
-
Morn,
Trenden er intakt https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/81048_RSI_60.JPG RSI onkring 60 på 5 års kort og mon ikke vi skal op mod de 80 inden næste retracement. Guiding (Feb 12) for 2020 bliver interessandt og afgørende for om trenden vil holde fremadrettet. Vi må se hvordan markedet taget imod forventet øget cashburn for 2020 og 2021 ( og ingen milestones) -
DnB Markets Rune Majlund Dahl
Genmab (Hold, TP: DKK1685.00) - Darzalex sales hit almost USD3bn
Johnson & Johnson (J&J) just reported 2019 Darzalex sales of USD2,998m. As per its licence agreement with Genmab, the USD150m sales milestone was triggered and Genmab therefore maintained its 2019 guidance (Genmab’s Q4 results due at 17:00 CET on 19 February). The milestone payment was in our 2020 estimates, but we have now moved it to 2019. We reiterate our HOLD and DKK1,685 target price -
A nice surprise for them that the milestone was reached last year instead of last year. It however also proves that it is not important in the long run, hence they maintain their target price. I wonder if other analytics would have shared that line of thought in case the milestone unexpected was not reached.
-
Thanks E L
-
*instead of this year
-
@Plimsoller let's just say that i am glad we did not have to test that lol
-
Agree
-
Pensionisten: Debatten i går aftes drejede sig ikke om fremtiden slet og ret. Den drejede sig om det fremtidige salg af Darzalex. Her har sc stor betydning. Hvis sc ikke kommer på markedet i større omfang i 2020, vil det få stor betydning for salget i 2020.
-
@StockBull Guiding for 2020 kommer vel i forbindelse med årsregnskabet
d. 19 februar? -
Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299 and in full pdf https://sci-hub.tw/https://clincancerres.aacrjournals.org/content/early/2020/01/22/1078-0432.CCR-19-2299
-
can you read this article in Denmark (it is blocked in NL) https://www.thetelegraph.com/business/article/J-J-looks-to-fend-off-challenges-to-key-drugs-14995067.php
-
No. Maybe one of the guys with VPN?
-
Johnson & Johnson posted weaker-than-expected sales in the final quarter of 2019, raising the stakes for the health-care conglomerate as it banks on new cancer and immunology drugs to replace a group of aging blockbusters.
Some of the company's most lucrative medicines are facing competition from generics and biosimilars. Arthritis drug Remicade's sales fell more than 16% from a year earlier in the quarter, while Zytiga, an older treatment for prostate cancer, saw a nearly 14% decline.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind